Fifty Percent Prevalence of Extracampine Hallucinations in Parkinson’s Disease Patients

Ruth A. Wood¹, Sarah A. Hopkins², Kuven K. Moodley¹ and Dennis Chan³*

¹Department of Medicine, Brighton and Sussex Medical School, Brighton, UK, ²Department of Medicine for the Elderly, Addenbrooke’s Hospital, Cambridge, UK, ³Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

Extracampine hallucinations (EH), the sense of a presence or fleeting movement in the absence of an associated visual percept, have been reported in Parkinson’s disease (PD) patients but their prevalence, characteristics, and temporal relationship to visual hallucinations (VH) remain unclear. Given that, VH are predictive of cognitive impairment in PD, improved understanding of EH may have significant prognostic implications. The objective of this study is to evaluate the prevalence and characteristics of EH in a large unselected population with PD and to assess the temporal relationship between EH, VH, and memory decline. Cross-sectional data were collected from 414 PD patients using a questionnaire circulated via an online patient community. Data were obtained regarding the occurrence, timing, and characteristics of VH and EH and symptoms of PD, disease duration, disease severity, and medication history. About 50.4% of respondents reported EH and 15.5% reported VH. EH were typically experienced alongside, rather than behind, the individual (p < 0.001) without clear lateralization (p = 0.438) and were more likely to be of unfamiliar presences (p < 0.001). The occurrence of EH was associated with Hoehn and Yahr score (p = 0.002) but not disease duration (p = 0.158).

EH onset was associated with VH onset (p = 0.046) and occurred after the onset of anosmia (p < 0.001), cognitive decline (p = 0.002), and sleep disturbance (p = 0.002). The reported prevalence of EH in PD patients was threefold greater than that of VH, with similar timings of onset, suggesting that EH are under-recognized and under-reported. Further work is needed to determine whether EH are predictive of cognitive decline.

Keywords: Parkinson’s disease, hallucinations, extracampine hallucinations, cortical Lewy body disease, visual hallucinations

INTRODUCTION

Hallucinations, defined as “sensory perceptions without external stimulation of the relevant sensory organ” (1), are a common feature of Parkinson’s disease (PD) and are a poor prognostic marker associated with increased risk of nursing home placement and cognitive decline (2, 3). Various types of hallucinations have been described in PD, including formed visual hallucinations (VH), auditory hallucinations, and extracampine hallucinations (EH), the latter denoting hallucinations occurring outside the visual field (campus, from Latin, field) (4, 5).

Of these hallucinations, VH are the most commonly described with the lifetime prevalence in PD patients approaching 75% (6). The presence of VH is typically a late feature of PD (4, 7) and is
predictive of cortical Lewy body pathology at post-mortem (8, 9). VH in PD are associated with the occurrence of cognitive dysfunction, daytime somnolence, and sleep disorders (4, 10, 11). Although their neural basis is not yet fully established, structural and functional neuroimaging studies have implicated a variety of brain systems, including anterior visual pathways, brainstem, and visual association regions in their pathogenesis (12). More specifically, evidence suggests a role for altered cortical visual processing in the pathogenesis of VH in PD (13).

In addition, antiparkinsonian drug therapy has been reported to precipitate psychosis (14, 15) with certain drugs, particularly dopaminergic agonists, being linked to VH in PD (16). However, dopaminergic drug use is not sufficient to explain the occurrence of all VH in PD (4). Furthermore, drug-induced psychosis in PD may persist even when the offending medication is withdrawn (17), and there appears to be a poor correlation between drug exposure and symptom severity (18).

In contrast to VH, EH (5) are not associated with any visual percep. Instead, EH are experienced as the sense of a presence beside or behind, or as a fleeting sense of movement alongside, the individual perceiving this phenomenon. In previous studies of hallucinoses associated with PD, EH have been classified as “minor hallucinations,” which, when combined with illusions, is associated with a prevalence ranging from 17 to 72% (4, 19–21). Several explanations exist for this wide range in reported prevalence, including heterogeneity of study populations and methodological differences in assessing the presence of these symptoms (21).

The occurrence of EH is not specific to PD; they have been reported in cerebrovascular disease, epilepsy, sleep paralysis, and traumatic brain injury (22–24). Aside from neurological disorders, EH have been described by individuals in situations associated with extreme physical hardship, such as shipwreck survivors, mountaineers, and polar explorers (25–27), perhaps most famously by Ernest Shackleton during his failed Antarctic expedition of 1914–1917.

... it seemed to me often that we were four, not three. I said nothing to my companions on the point, but afterwards Worsley said to me, ’Boss, I had the curious feeling on the march that there was another person with us’ (25)

In the context of neurodegenerative diseases, the presence of VH is a relatively specific feature of cortical Lewy body disease (9, 28) and forms one component of the diagnostic criteria for Dementia with Lewy Bodies (DLB) and Parkinson’s Disease Dementia (8, 29). Given that, VH are predictive of future cognitive decline (30–32), it is possible that other types of hallucinosis may also have predictive value, notably those likely to be indicative of cortical involvement.

Extracampine hallucinations are by definition less overt than VH, and therefore may be both under-reported by patients and under-investigated by clinicians, who do not routinely include questions about EH in their history taking (5). Additionally, while the neural substrate of EH has yet to be clarified, their phenomenological nature would implicate higher order association cortices in EH generation beyond any reasonable doubt. As such, it is important to establish whether EH represent a cortical marker of disease in patients with PD, and thus are predictive of future cognitive and clinical decline. Such determination would have major implications for biomedical research, in terms of disease phenotyping and natural history studies, and for clinical practice, with the assessment of EH in patients with PD potentially acting as a prognostic marker alerting clinicians to impend cognitive decline. In practice, EH focused questions could be included in the routine clinical history or, in the future, could be assessed in specialist PD clinics using a validated EH questionnaire similar to those currently in use for the assessment of VH (33).

However, prior to any such studies, the first step is to obtain a better understanding of the occurrence of EH in patients with PD, in view of the limited information available at present. The primary objective of this study was therefore to determine the prevalence of EH in patients with PD. The secondary objectives are to identify the main characteristics of EH (for example, emotional content, familiarity of percept, laterality of EH) and to assess the temporal relationship between the onset of EH and other key symptoms of PD, specifically VH, cognitive impairment, and REM sleep behavior disorders. In order to obtain these data from a more representative sample of PD patients, and thus offset the potential ascertainment bias associated with sampling from a specialist PD clinics, information about EH occurrence were acquired by way of a web-based questionnaire made available to an online social networking community of patients, patientslikeme® (34).

MATERIALS AND METHODS

Recruitment and Administration of Questionnaire

patientslikeme® is an online patient network where members share personal health data to track their disease progression, communicate with other patients, and contribute to research studies. Members of the community are regularly invited to participate in optional questionnaire-based research studies (34). Although patients with any illness are able to sign up to the website, patientslikeme® has a large online community of individuals with PD; at the time of this study, there were 6841 such members.

All members of the patientslikeme® community who had previously self-identified as having PD were invited to participate in the study via email (Figure 1). The link provided in the email enabled potential participants to access the study information and indicate whether or not they wished to participate. Submission of the completed questionnaire was interpreted as provision of consent for study enrollment in line with ethical guidelines from The University of Sussex on the acquisition of anonymous questionnaire-based data from patient groups (35). The online survey remained open for 1 week and to verify the test–retest reliability of the EH questionnaire and, in line with routine practice in questionnaire-based surveys hosted on the patientslikeme® platform, all participants were invited by email to complete a retest phase 2 weeks later in which an identical questionnaire was administered.
Ethics
Ethical approval for this study was obtained from the South East Coast – Surrey Regional Ethics Committee (reference number 12/LO/1001).

Inclusion/Exclusion Criteria
Those included in the study were adults with a self-reported diagnosis of PD. Respondents were excluded if they had self-reported Lewy body dementia, PD with associated dementia, a non-PD neurodegenerative disorder, or moderate-to-severe visual impairment (cataracts, macular degeneration, diabetic eye disease, or registered blind).

Questionnaire
The study instrument was a novel, web-based, questionnaire, which was completed via the patientslikeme® online platform. The questions were generated by the study authors with input from patients with PD and their caregivers. Participants were informed of the nature of the study in terms of the information being requested but were blinded to the specific hypotheses being tested, in order to eliminate reporting bias. In order to increase the response rate, an email reminder was sent after the initial launch.

All data were self-reported and information was gathered regarding demographics, co-morbidities, and current and previous experiences of illusions (Q1, Table 1), VH (Q22–26), and EH (Q2–21). Two questions were used to assess whether or not participants had experienced EH (Q2 and Q6) and a participant was defined as having had an EH if they answered yes to one or both of these questions.

Participants were asked to characterize EH in terms of EH location relative to themselves (Q3), laterality (Q4), emotional content (Q28), time of day of occurrence (Q5), form (Q7), and familiarity (Q8). They were also asked about any auditory or tactile (Q9–10) components, whether their EH were stereotyped (Q11) and the effect of medications on their EH, in terms of aggravation or amelioration (Q12–14). All known trade names for PD medications were used, to help ensure correct identification of medications used by participants from different countries.

Data were also collected regarding the relationship between the onset of EH and other features of disease, such as VH, memory decline, anosmia, and sleep disturbance. Disease severity was assessed using a modified version of the Hoehn and Yahr score, already in use by patientslikeme®, in which patients identify their disease severity (Table 1).

Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics Version 22.0. Descriptive statistics were used to analyze the characteristics of EH in terms of laterality (left/right), familiarity (familiar/unfamiliar), emotional content (pleasant/unpleasant/neither), associated emotional response (happy/sad/neither), and time of day (morning/afternoon/evening/night). Chi-squared testing was undertaken to determine whether there were significant differences between the expected and observed frequencies of these variables.

Respondents were divided into two groups, those with EH and those without, and the distribution of variables, such as age, gender, disease duration, and severity and presence of VH within these groups were compared using an independent t-test, Mann–Whitney U, or a chi-squared test (with or without trend) depending on whether the variable being analyzed was continuous or categorical and normally distributed. Normality of data was assessed using visual inspection of histograms, QQ plots and box plots, and Shapiro–Wilk testing.

A logistic regression analysis was undertaken to determine if a set of pre-specified variables (age, gender, disease duration, disease severity as specified by Hoehn and Yahr score, and presence of VH) were predictive of the occurrence of EH (36). These potential predictor variables were selected based on prior clinical knowledge and pre-specified hypotheses, explicitly that the prevalence of EH would not be influenced by demographic factors, such as age and sex, but would be affected by disease duration, disease severity, and VH, putative correlates of accumulating cortical Lewy Body pathology. A Box–Tidwell test was used to ensure there was linearity for continuous and transformed categorical variables. The dependent variable, the occurrence of EH, was dichotomous and assigned a value of 1 (EH occurrence) or 0 (no EH occurrence).

RESULTS
Recruitment
Data from 414 respondents were included in the study. Of the 6841 individuals with PD who were invited to participate, 569 responded indicating a response rate of 8.3%. Forty (9.7%) respondents were excluded as they had not completed the questionnaire, and 115 (20.2%) were excluded on the basis of the exclusion criteria outlined above.

Participant Demographics
The mean age of respondents was 61.9 years (standard deviation 8.2 years, range 33–88 years) and 48.2% (199/413) of the cohort were female. About 83.5% (324/388) of participants were
TABLE 1 | Questionnaire items as posed to participants.

| Illusions | Modified Hoehn and Yahr score |
|-----------|-------------------------------|
| Q1. Have you ever looked at something and thought it was something else altogether? |
| Q2. Have you ever experienced a feeling of movement past you when there was nothing there to account for this feeling? |
| Q3. Where was the feeling of movement in relation to you? Front/Behind/To the side |
| Q4. If to the side, do they occur more on the left or the right? Mostly on the left/Mostly on the right/There is no pattern/Does not apply |
| Q5. Are these experiences more common at a particular time of day? Morning/Afternoon/Evening/Night/There is no pattern |
| Q6. Have you ever felt of imagined a presence either behind or alongside you when there was nothing there to account for this feeling? |
| Q7. Do you feel as though this presence is human, animal or other? Human/Animal/Other |
| Q8. Is the presence familiar to you? Yes/No |
| Q9. Does the presence ever speak to you or make another noise? Yes/No |
| Q10. Does the presence ever touch you? Yes/No |
| Q11. Are these experiences always the same? Yes/No |
| Q12. Have any of your medications ever made these experiences better OR worse? Yes/No |
| Q13. If you have ever taken any of the following medications* please indicate how they affected these experiences. Improved symptoms/Worsened symptoms/No effect on my symptoms/I have never taken this medication |
| Q14. If you have ever taken any other medications for your Parkinson’s disease, please indicate what these were and how they affected these experiences |
| Q15. Do you have a reduced sense of smell? Yes/No |
| Q16. Have you noticed a decline in your memory or thinking? Yes/No |
| Q17. Have you noticed a change in your ability to walk or maintain balance? Yes/No |
| Q18. Have you noticed that your sleeping has become more restless or disturbed? Yes/No |
| Q19. Did you notice this before or after you FIRST noticed the presence? Before/After |
| Q20. Are you able to estimate how much time passed between noticing this and first becoming aware of a presence? Yes, I can/No, I cannot |
| Q21. If yes, please estimate this period (in days, weeks, months, or years) |
| Q22. Have you ever SEEN things that were not really present or that other people could not see? (For example, some patients report seeing animals or children that others cannot see.) Yes/No |
| Q23. If you answered YES, when did this occur in relation to feeling/imaging the sense of a presence? Before/After/They occurred at the same time/I am not sure which occurred first |
| Q24. If you answered BEFORE or AFTER please estimate this period (in days, weeks, months or years) |
| Q25. How often do you see things that are not really present or that other people cannot see? Less than once a week/At least once a week/Several times a week |
| Q26. What do you generally see during these episodes? The images are not fully formed/I see adult beings/I see children/I see animals or insects/I see shadows that may sometimes move/I see other everyday objects |
| Q27. When was the last time this happened? Within the last week/Within the last month/Within the last 3 months/Within the last 6 months/More than 6 months ago |
| Q28. These experiences are: Pleasant or reassuring/Unpleasant or frightening/Neither |
| Q29. These experiences make me feel: Happy/Sad/Neither |
| Q30. I sometimes have very vivid dreams Yes/No |
| Q31. I have been told that I kick and/or punch in my sleep Yes/No |
| Q32. I have been told that I shout, swear or laugh in my sleep Yes/No |

In addition to the potential responses listed, participants were also able to skip the question.

*Co-careDopa, Co-benylDopa, Stalevo, Rodigotine, Pramipexole, Ropinirole, Benzotropine, Trihexyphenidyl, Selegiline, Rasagiline, Entacapone, Amantadine, Rivastigmine, Donepezil, Galantamine.

Prevalence of Hallucinations

About 33.9% (140/413) of respondents reported illusions and 15.5% (64/412) had experienced VH. More than half of respondents reported EH; 45.9% (190/414) reported a “feeling of movement” passing them and 24.6% (102/414) reported “feeling or imaging a presence that was not truly there.” Given that, 20.3%
Wood et al. Extracampine Hallucinations in PD

reported both symptoms, 50.4% (208/413) experienced either a "feeling of movement" or had "felt or imagined a presence" (Figure 2).

Predictors of EH
Neither age nor gender was predictors for the occurrence of EH (Table 2). Mean disease duration did not differ significantly between the EH and non-EH groups (p = 0.158), but those with EH were more likely to have a higher Hoehn and Yahr Stage (p = 0.002) (Table 2).

Characteristics of EH
Extracampine hallucinations were more likely to occur alongside rather than directly in front of or behind the person experiencing them (p < 0.001) (Table 3). Although EH did lateralize to the left or right in 47.0% (78/166) of cases this was a non-significant finding (p = 0.438) with a similar proportion of respondents (53.0%, 88/166) stating either that there was no left/right pattern or that they had not noticed such a pattern. Of the 47.0% (78/166) that did lateralize more were reported on the right side but this did not reach statistical significance (p = 0.070).

Extracampine hallucinations were more likely to feel “unfamiliar” than “familiar” (p = 0.001) and seemed to be emotional neutral experiences making people feel neither happy nor sad (p < 0.001), and neither pleasant nor unpleasant, whether they had reported “a feeling of movement” (p < 0.001) or the “sense of a presence” (p < 0.001) (Table 3).

Timing of EH
In those who reported EH these were often recently experienced; 81.6% (151/185) of those who reported a “feeling of a movement passing them” and 72.3% (73/101) of those who reported a “felt or imagined presence” had experienced this phenomenon within the previous three months. EH were not associated with a particular time of day (morning/afternoon/evening/night) (p < 0.001).

Relationship Between EH and Other Symptoms Associated with PD
Extracampine hallucinations co-existed with other PD symptoms. Of those who reported EH, 75.5% (77/102) also had anosmia, 73.3% (74/101) reported a decline in their memory or thinking, 72.5% (74/102) had restless sleep, and 77.4% (27/35) had experienced a change in their balance or walking.

The onset of anosmia, memory decline, and sleep disturbance were all more likely to precede the onset of EH in our cohort (p < 0.001, p = 0.002, and p = 0.002, respectively), but there was no clear temporal relationship between the onset of EH and the onset of motor symptoms (p = 0.221) in line with the above finding of a lack of association between EH and disease duration (Table 4).

Relationship Between EH and VH
In 52.8% (19/36) of reported cases, EH onset was described as occurring around the same time as VH, with 25% (9/36) and 22.2% (8/36), respectively, reporting EH onset before and after VH onset. This finding reached statistical significance (p = 0.046) (Table 4).

A major overlap was observed between those reporting VH and those reporting EH (Figure 2); 85.9% of those with VH also had EH. Those who reported EH were significantly more likely to report VH (26.6%, 55/207) than those who did not report EH (4.4%, 9/204) (p < 0.001) (Table 4). About 37.0% (152/411) of all respondents reported EH but no VH, and 2.2% (9/411) reported VH but no EH (Figure 2).
Predictors of EH

A binary logistic regression was performed to ascertain the effects of age, gender, disease duration, disease severity (Hoehn and Yahr score), and the presence of VH on the likelihood that the participants had experienced EH. The logistic regression model was statistically significant [$\chi^2(5) = 44.463, p < 0.001$] and explained 13.9% (Nagelkerke $R^2$) of the variance in the presence of EH. Overall, it correctly predicted the occurrence or absence of EH in 62.4% of respondents; it correctly classified 37.9% of those experiencing EH and 87.1% of those not experiencing EH. Of these variables, only the presence of VH was found to be significantly predictive of EH occurrence (Table 4).

Medication

Participants who had experienced EH were asked if their medications made their EH better or worse. Overall medications did not appear to have an effect upon EH ($p < 0.001$) with 72.6% (69/95) of respondents stating they had not noticed an effect.

27.4% (26/95) reported that their medication had affected their EH and provided further data regarding individual drugs (Table 4). The following data were collected only from these 26 participants therefore the number of responses for each drug was small. For some drugs (co-benylodopa, stalevo, benzotropine, trihexyphenidyl, entacapone, rivastigmine, donepezil, and galantamine), information was obtained from fewer than five respondents, and these small sample sizes precluded meaningful interpretation; for example, only three patients in this subgroup were taking rivastigmine. Of the remaining drugs, 13/17 respondents stated that pramipexole significantly worsened EH ($p = 0.010$). No significant drug effect on EH was noted for other drugs (Table 4).

Test–Retest Reproducibility of Responses

52.9% (301/569) of participants completed a retest phase in which they retook an identical questionnaire. Analysis of this data by patientslikeme indicated that our questionnaire had a high test–retest reliability (Cronbach $\alpha = 0.94$).

DISCUSSION

The prevalence of EH in patients with PD, their characteristics and association with other key clinical features of PD were investigated using a web-based questionnaire circulated to the online patient community patientslikeme. To the best of our knowledge, this is the first large cross-sectional study to focus on the occurrence of EH in patients with PD. The main finding of the study was that EH were reported by over 50% of respondents, representing a prevalence more than three times greater than that of VH (50.4 versus 15.5%). Although there is no prior study specifically exploring the prevalence of EH in PD against which these study results can be compared, this 50.4% prevalence figure falls within the range of reported prevalences of minor hallucinations in PD (4, 19–21), which includes EH.

Extracampine hallucinations were significantly more likely to be experienced as a presence alongside, rather than behind, the individual ($p < 0.001$), to be an unfamiliar rather than a familiar presence ($p < 0.001$), for the presence to be that of a...
person rather than an animal or inanimate object \((p < 0.001)\), and to be emotionally neutral in content \((p < 0.001)\). EH did not tend to be stereotypical in nature \((p < 0.001)\), and did not tend to have an auditory or tactile component \((p < 0.001)\). There was no significant association between occurrence of EH and time of day \((p < 0.001)\).

With regard to other aspects of PD, there was a statistically significant \((p = 0.002)\) association between EH occurrence and disease severity, as measured by the Hoehn and Yahr stage, but not with respondent age, gender, and disease duration of PD. The presence of VH was predictive of EH and the majority of respondents who reported EH also described VH \((85.9\%)\). In over 50\% of respondents, EH and VH onset occurred around the same time.

Surprisingly, and in contrast to previous studies reporting that the onset of VH was predictive of future cognitive decline, in this study respondents stated that EH occurred after the onset of cognitive problems, as well as after anosmia and sleep disturbance. This was an unexpected finding. One possibility is that these results may be skewed by the greater difficulty in recognizing the onset of EH, given its current under-reporting and under-recognition. However, another possibility is that the Lewy body pathology may affect the cortical systems underpinning EH later than those involved in cognition. That said, this would seem a less plausible explanation when the neural substrate of EH is considered. While this is yet to be established, given that EH represent percepts that are by definition devoid of any visual form, it is probable that they are of cortical origin rather than indicative of a disorder of primary sensory pathways. This is reinforced by a recent study investigating the imaging changes associated with the “sense of a presence,” both in a small cohort of patients with neurological disorders (epilepsy, stroke but no PD patients) and healthy subjects in whom this phenomenon was induced artificially using synchronous and asynchronous stimulation \((37)\). The brain regions most commonly associated with “the sense of a presence” were the frontoparietal cortex, insular cortex, and temporoparietal cortex. With regard to the latter, the clinicopathological observation that VH in Lewy body disease were strongly associated with a high density of Lewy bodies in the temporal lobe \((9)\) may provide a clue as to the cortical substrate of EH. Given that, the onset of VH commonly precedes that of cognitive impairment in PD, the expectation might have been that the latter would also be preceded by the occurrence of EH. This will need to be clarified by way of future prospective natural history studies of EH in PD patients without cognitive impairment.

Insufficient data were generated to draw any firm conclusions regarding the effect of medications on EH. Although the majority of patients reported that their medications did not influence

| Variable                      | Coefficient | SE  | Odds ratio | 95% Confidence limits | p-Value |
|-------------------------------|-------------|-----|------------|-----------------------|---------|
| Age                           | 0.006       | 0.013 | 0.994     | 0.981 - 1.032         | 0.644   |
| Sex                           | 0.213       | 0.212 | 1.273     | 0.817 - 1.873         | 0.315   |
| Disease duration              | -0.002      | 0.023 | 0.927     | 0.955 - 1.043         | 0.927   |
| H&Y score                     | 0.162       | 0.114 | 1.176     | 0.941 - 1.470         | 0.154   |
| VH                            | 1.958       | 0.380 | 7.083     | 0.067 - 0.297         | <0.001  |

**C** **(C) Medication effect on EH (data from 26/95 participants whose medication affected EH)**

| Medication       | Number of responders | EH better (%) | EH worse (%) | No effect (%) | p-Value* |
|------------------|----------------------|---------------|--------------|---------------|---------|
| Co-careldopa     | 24                   | 8 (33)        | 5 (21)       | 11 (46)       | 0.325   |
| Rotigotine       | 7                    | 0 (0)         | 4 (57)       | 3 (42)        | 0.160   |
| Pramipexole      | 17                   | 1 (6)         | 13 (76)      | 3 (18)        | 0.010   |
| Ropinirole       | 18                   | 2 (11)        | 9 (50)       | 7 (39)        | 0.229   |
| Selegiline       | 7                    | 0 (0)         | 2 (29)       | 5 (71)        | 0.066   |
| Rasagline        | 12                   | 0 (0)         | 1 (8)        | 11 (92)       | <0.001  |
| Amantadine       | 12                   | 3 (25)        | 4 (33)       | 5 (42)        | 0.779   |

EH, extracampine hallucinations; VH, visual hallucinations.

* Chi squared testing.
† Data not requested on the questionnaire.

Bold font denotes statistically significant results with a cut off of \(p < 0.05\).
their EH, a minority did notice an effect with the only significant finding being that pramipexole worsened EH.

This study has limitations. The use of a web-based questionnaire to obtain responses from an online community of patients not diagnosed, or under the care of, the study authors means that there is no mechanism to confirm the diagnosis of PD or the Hoehn and Yahr score. Knowledge is also lacking on the demographic details of the respondent group and given the online nature of both the community and the questionnaire, it is possible that the respondents as group may not reflect the entire socio-economic breadth of the wider PD patient population. Additionally, this study is potentially vulnerable to the biases associated with all questionnaire-based research studies (selection, recall, and responder bias). With regard to disease severity of the study respondents, the mean Hoehn and Yahr score was 2.1, which may reflect the fact that patients with more severe disease could find completing online questionnaires more challenging. Finally, in order to ensure some degree of homogeneity among the test respondents as group may not reflect the entire socio-economic and in particular offer thanks to Paul Wicks, Ph.D. (Vice President of Innovation at patientslikeme®) for his assistance in setting up this collaboration, and to Magdalena Harrington, Ph.D. (Psychometrician at patientslikeme®) and Julia Braverman, Ph.D. (Research Scientist at patientslikeme®) for technical support in setting up the online questionnaire and obtaining the data. We also wish to thank Dr. Stephen Brenmer, Ph.D. (Senior Lecturer in Medical Statistics at Brighton and Sussex Medical School) for his assistance with the statistical analysis.

CONCLUSION

The occurrence of EH in 50.4% of respondents suggests that EH is an under-reported and under-recognized symptom of PD.

REFERENCES

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Association (2013).
2. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology (1993) 43:2227–9. doi:10.1212/WNL.43.11.2227
3. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord (2004) 19:1043–9. doi:10.1002/mds.20216
4. Felenon G, Mahieux F, Flouon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain (2000) 123(Pt 4):733–45. doi:10.1093/brain/123.4.733
5. Chan D, Rossor MN. “but who is that on the other side of you?” Extracampine hallucinations revisited. Lancet (2002) 360:2064–6. doi:10.1016/S0140-6736(02)11998-2
6. Diederich NJ, Felenon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol (2009) 5:331–42. doi:10.1038/nrneurol.2009.62
7. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol (2005) 4:605–10. doi:10.1016/S1474-4422(05)70146-0
8. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 47:1113–24. doi:10.1212/WNL.47.5.1113
9. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain (2002) 125:391–403. doi:10.1093/brain/awf033

Given that, the occurrence of VH represents one of the core criteria for the diagnosis both of PDD and DLB, identification of EH may be of high clinical significance The likely neural substrate of this phenomenon suggests that EH may indicate cortical involvement in PD and thus be predictive of future cognitive decline.

ACKNOWLEDGMENTS

The authors would like to thank all the study respondents and patientslikeme® for their collaboration with this research project and in particular offer thanks to Paul Wicks, Ph.D. (Vice President of Innovation at patientslikeme®) for his assistance in setting up this collaboration, and to Magdalena Harrington, Ph.D. (Psychometrician at patientslikeme®) and Julia Braverman, Ph.D. (Research Scientist at patientslikeme®) for technical support in setting up the online questionnaire and obtaining the data. We also wish to thank Dr. Stephen Brenmer, Ph.D. (Senior Lecturer in Medical Statistics at Brighton and Sussex Medical School) for his assistance with the statistical analysis.

FUNDING

Dr. RW is funded by the UK National Institute for Health Research (NIHR). Dr. DC is funded by the Cambridge NIHR Biomedical Research Centre and receives grant income from the UK Medical Research Council, Technology Strategy Board and the Cambridge Isaac Newton Trust. There are no other financial disclosures to make.

10. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol (1996) 53:1265–8. doi:10.1001/archneur.56.5.595
11. Gallagher DA, Parkkinen L, O’Sullivan SS, Spratt A, Shah A, Davey CC, et al. Testing an aetiological model of visual hallucinations in Parkinson’s disease. Brain (2011) 134:3299–309. doi:10.1093/brain/awr225
12. Ibarrette-Bilbao N, Junque C, Marti MJ, Tolosa E. Cerebral basis of visual hallucinations in Parkinson’s disease: structural and functional MRI studies. J Neurol Sci (2011) 310:79–81. doi:10.1016/j.jns.2011.06.019
13. Stebbins GT, Goetz CG, Carrillo MC, Bangen KJ, Turner DA, Glover GH, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology (2004) 63:1409–16. doi:10.1212/01.WNL.0000141853.27081.BD
14. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry (1982) 139:494–7. doi:10.1176/ajp.139.4.494
15. Cummings JL. Behavioral complications of drug treatment of Parkinson’s disease. J Am Geriatr Soc (1991) 39:708–16. doi:10.1111/j.1532-5415.1991.003627.x
16. Rascò O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke GE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med (2000) 342:1484–91. doi:10.1056/NEJM200005183421404
17. Friedman JH. ‘Drug holidays’ in the treatment of Parkinson’s disease. A brief review. Arch Intern Med (1985) 145:913–5. doi:10.1001/archinte.145.5.913
18. Aarsland D, Larsen JP, Cummings JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol (1999) 56:595–601. doi:10.1001/archneur.56.5.595
19. Pacchetti C, Manni R, Zangaglia R, Mancini F, Marchioni E, Tassorelli C, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. *Mov Disord* (2005) **20**:1439–48. doi:10.1002/mds.20582

20. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson’s disease from atypical parkinsonism. *J Neural Neurosurg Psychiatry* (2008) **79**:652–5. doi:10.1136/jnnp.2007.124677

21. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. *J Neural Sci* (2010) **289**:12–7. doi:10.1016/j.jns.2009.08.014

22. McDonald I. Musical alexia with recovery: a personal account. *Brain* (2006) **129**:2554–61. doi:10.1093/brain/awl235

23. Solomonova E, Nielsen T, Stenstrom P, Simard V, Frantova E, Donderi D. Sensed presence as a correlate of sleep paralysis distress, social anxiety and waking state social imagery. *Conscious Cogn* (2008) **17**:49–63. doi:10.1016/j.concog.2007.04.007

24. Zijlmans M, van Eijsden P, Ferrier CH, Kho KH, van Rijen PC, Leijten FS. Illusory shadow person causing paradoxical gaze deviations during temporal lobe seizures. *J Neural Neurosurg Psychiatry* (2009) **80**:686–8. doi:10.1136/jnnp.2008.154310

25. Shackleton E. *South*. London: William Heinemann (1919).

26. Critchley M. *Shipwreck Survivors: A Medical Study*. London: JaAC Ltd (1943).

27. Brugger P, Regard M, Landis T, Oelz O. Hallucinatory experiences in extreme-altitude climbers. *Neuropsychiatry Neuropsychol Behav Neurol* (1999) **12**:67–71.

28. Bertram K, Williams DR. Visual hallucinations in the differential diagnosis of parkinsonism. *J Neural Neurosurg Psychiatry* (2012) **83**:448–52. doi:10.1136/jnnp-2011-300980

29. Emre M, Aarsland D, Brown R, Burn DJ, Duycckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. *Mov Disord* (2007) **22**:1689–707; [quiz 1837]. doi:10.1002/mds.21507

30. Kitayama M, Wada-Isoe K, Nakaso K, Iritaya Y, Nakashima K. Clinical evaluation of Parkinson’s disease dementia: association with aging and visual hallucination. *Acta Neurol Scand* (2007) **116**:190–5. doi:10.1111/j.1600-0404.2007.00860.x

31. Ramirez-Ruiz B, Junque C, Marti MJ, Valdeoriola F, Tolosa E. Cognitive changes in Parkinson’s disease patients with visual hallucinations. *Dement Geriatr Cogn Disord* (2007) **23**:281–8. doi:10.1159/000100850

32. Lee WJ, Tsai CF, Gauthier S, Wang SJ, Fuh JL. The association between cognitive impairment and neuropsychiatric symptoms in patients with Parkinson’s disease dementia. *Int Psychogeriatr* (2012) **24**:1980–7. doi:10.1017/S1041610212001317

33. Goetz CG. Scales to evaluate psychosis in Parkinson’s disease. *Parkinsonism Relat Disord* (2009) **15**(Suppl 3):S38–41. doi:10.1016/S1353-8020(09)70777-1

34. Smith CA, Wicks PJ. PatientsLikeMe: consumer health vocabulary as a folksonomy. *AMIA Annu Symp Proc* (2008) **2008**:682–6.

35. Sussex. *Guidelines for Completing the Online Application Form for Ethical Review. Point 14* (2012) 10 p. Available from: https://www.sussex.ac.uk/webteam/gateway/file.php?name=guidance-for-completing-online-application-form.pdf&site=377

36. Field A. *Discovering Statistics Using IBM SPSS Statistics*. 4th ed. Thousand Oaks, CA: SAGE (2013).

37. Blanke O, Pozeg P, Hara M, Heydrich L, Serino A, Yamamoto A, et al. Neurological and robot-controlled induction of an apparition. *Carr Biol* (2014) **24**:2681–6. doi:10.1016/j.cub.2014.09.049

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Wood, Hopkins, Moodley and Chan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.